Response‐adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T‐cell therapy in relapsed/refractory large B‐cell lymphoma: A retrospective observationa... by Rong Shen, Wei‐Guo Cao, Li Wang, Ling‐Shuang Sheng, Yi‐Lun Zhang, Wen Wu, Peng‐Peng Xu, Shu Cheng, Meng‐Ke Liu, Yan Dong, Yue Wang, Xiang‐Qin Weng, Xu‐Feng Jiang, Qi Song, Hong‐Mei Yi, Lei Li, Sheng Chen, Zi‐Xun Yan, Wei‐Li Zhao

Get full text